Pfizer sues for Lipitor protection till 2016

Pfizer is hitting back at would-be Lipitor copycat Ranbaxy. The drugs giant sued the generics maker for patent infringement over the blockbuster cholesterol med Lipitor and Caduet, a combo of Lipitor and blood-pressure med Norvasc. Already blocked from selling copycat versions of the drugs till 2010, Ranbaxy would be stymied till 2016 if Pfizer's legal maneuvering succeeds.

Lipitor, of course, is Pfizer's cash cow, with $12.7 billion in 2007 sales, more than a quarter of the company's revenues; Caduet brought in $568 million. The suits allege that generic Lipitor and Caduet would trample on two Lipitor process patents, which don't expire until 2016. Pfizer asked the court to ban Ranbaxy from making, selling, or importing generic Lipitor till then. A Canadian court recently ruled in Pfizer's favor, protecting Lipitor from Ranbaxy until 2010.

- read the article at MarketWatch
- see the story at India Infoline
- check out Pfizer's release on the Canadian ruling

ALSO: EMTs to Lipitor's rescue? A union representing emergency medical techs and paramedics recently mailed a letter to its doctors' network endorsing the cholesterol med. "When appropriate, we ask that you please consider an agent like Lipitor for our members with high cholesterol," an official of the International Association of EMTs and Paramedics wrote. "IAEP leadership stands behind Lipitor as the lipid-lowering agent of choice." Report

Suggested Articles

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.